53 results on '"Langkilde, Anna-Maria"'
Search Results
2. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial
3. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
4. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial
5. Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction
6. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
7. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
8. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status
9. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
10. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER
11. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
12. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
13. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF
14. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER
15. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
16. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
17. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure
18. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction
19. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
20. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF
21. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial
22. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
23. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
24. The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
25. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
26. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
27. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
28. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
29. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
30. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
31. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
32. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
33. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
34. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF
35. The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure
36. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
37. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial
38. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
39. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
40. Sex Differences in Heart Failure With Improved Ejection Fraction: The DELIVER Trial
41. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
42. SEX DIFFERENCES IN HEART FAILURE WITH IMPROVED EJECTION FRACTION: THE DELIVER TRIAL
43. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL
44. WCN24-1229 EFFECTS OF TREATMENT AND CLINICAL EVENTS ON QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A PRESPECIFIED ANALYSIS OF THE DAPA-CKD TRIAL
45. WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
46. GEOGRAPHICAL VARIATION IN PATIENT CHARACTERISTICS AND OUTCOMES IN HFPEF
47. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL
48. CA125 IN PATIENTS WITH HFREF AND THE EFFECT OF DAPAGLIFLOZIN: INSIGHTS FROM DAPA-HF
49. THE EFFECT OF DAPAGLIFLOZIN ON INSULIN INITIATION OR INTENSIFICATION IN PATIENTS IN HEART FAILURE AND DIABETES: A POOLED ANALYSIS OF DAPA-HF AND DELIVER
50. Effects of high-resistant-starch banana flour (RS2) on in vitro fermentation and the small-bowel excretion of energy, nutrients, and sterols: an ileostomy study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.